PDMO
LIVE

Serial Number

90406176

Owner

Sterling Pharma Solutions Limited

Attorney

Sarah Anne Keefe

Filing Date

Dec 23, 2020

Add to watchlist:

No watchlists yet
View on USPTO

PDMO Trademark

Serial Number: 90406176 • Registration: 6909412

PDMO is a trademark filed by Sterling Pharma Solutions Limited on December 23, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Sterling Pharma Solutions Limited (3 trademarks)

Cramlington
Northumberland NE237QG , GB

Entity Type: 99

Trademark Details

Filing Date

December 23, 2020

Registration Date

November 29, 2022

Published for Opposition

September 13, 2022

Goods & Services

Custom manufacture of pharmaceuticals; processing of pharmaceuticals, namely treatment in the nature of chemical processing of chemical, biochemical and pharmaceutical products for third parties; custom manufacturing services in the nature of processing of pharmaceutical preparations; processing of pharmaceutical preparations, assembly of products for others, namely, processing of pharmaceuticals, medicines, and biological preparations to the order and specification of others; treatment in the nature of chemical processing of chemical, biochemical and pharmaceutical products for third parties; treatment of materials, namely, pharmaceutical, biologic, and chemical products and their components used in the manufacture of pharmaceuticals, biotherapeutic products, and biopharmaceuticals; treatment and destruction of pharmaceutical waste; information, advice and consultancy services in relation to the aforesaid services

Pharmaceuticals, namely, psychotropics, antihelmintics, anti-infectives, lipid lowering agents, inducers of erections, induction agents, neuromuscular blocking agents, sedatives, anti-cancer medication, anti-inflammatories, anti-fungals, anti-bacterials, anti-spasmodics, appetite stimulants, bronchodilators, appetite suppressants, anti-convulsives, neuroprotective drugs, anti-anxiety medication, anti-depressants, anti-ischemics, anti-psychotics; pharmaceutical preparations for treating diabetes, ear, nose and throat disorders, epilepsy, genetic disorders, hematological disorders, hormonal disorders, infectious diseases, lymphoma, metabolic disorders, mouth and dental disorders, musculoskeletal disorder, non-malignant disorder, nutritional disorders, pain, rare ophthalmological diseases, rare cancers, rare infectious diseases, rare genetic diseases, rare respiratory diseases, rare central nervous system diseases, rare gastrointestinal diseases, rare immunological diseases, rare cardiovascular diseases, rare dermatological diseases, rare urinary system and sex hormone diseases, rare womens health diseases, and rare ear, nose, and throat diseases; Pharmaceuticals, namely, pharmaceutical preparations and substances for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders for medical or veterinary purposes; vaccines; medicine for treating diabetes, ear, nose and throat disorders, epilepsy, genetic disorders, hematological disorders, hormonal disorders, infectious diseases, lymphoma, metabolic disorders, mouth and dental disorders, musculoskeletal disorder, non-malignant disorder, nutritional disorders, pain, rare ophthalmological diseases, rare cancers, rare infectious diseases, rare genetic diseases, rare respiratory diseases, rare central nervous system diseases, rare gastrointestinal diseases, rare immunological diseases, rare cardiovascular diseases, rare dermatological diseases, rare urinary system and sex hormone diseases, rare womens health diseases, and rare ear, nose, and throat diseases; chemical preparations for use in the pharmaceutical industry, namely for treating diabetes, ear, nose and throat disorders, epilepsy, genetic disorders, hematological disorders, hormonal disorders, infectious diseases, lymphoma, metabolic disorders, mouth and dental disorders, musculoskeletal disorder, non-malignant disorder, nutritional disorders, pain, rare ophthalmological diseases, rare cancers, rare infectious diseases, rare genetic diseases, rare respiratory diseases, rare central nervous system diseases, rare gastrointestinal diseases, rare immunological diseases, rare cardiovascular diseases, rare dermatological diseases, rare urinary system and sex hormone diseases, rare womens health diseases, rare ear, nose, and throat diseases, animal health disorders, cardiovascular diseases and disorders, central nervous system disorders, dermatologic disorders, endocrine system disorders, gastrointestinal diseases, genito urinary system and sex hormone imbalances, male health disorders, women's health disorders, mental health disorders, musculoskeletal disorders, renal disorders, cancer, ophthalmic disorders, renal diseases, respiratory diseases, trauma and injury

Active chemical ingredients for use in the manufacture of pharmaceuticals for treating diabetes, ear, nose and throat disorders, epilepsy, genetic disorders, hematological disorders, hormonal disorders, infectious diseases, lymphoma, metabolic disorders, mouth and dental disorders, musculoskeletal disorder, non-malignant disorder, nutritional disorders, pain, rare ophthalmological diseases, rare cancers, rare infectious diseases, rare genetic diseases, rare respiratory diseases, rare central nervous system diseases, rare gastrointestinal diseases, rare immunological diseases, rare cardiovascular diseases, rare dermatological diseases, rare urinary system and sex hormone diseases, rare womens health diseases, rare ear, nose, and throat diseases, animal health disorders, cardiovascular diseases and disorders, central nervous system disorders, dermatologic disorders, endocrine system disorders, gastrointestinal diseases, genito urinary system and sex hormone imbalances, male health disorders, women's health disorders, mental health disorders, musculoskeletal disorders, renal disorders, cancer, ophthalmic disorders, renal diseases, respiratory diseases, trauma and injury

Pharmaceutical research services; pharmaceutical drug development services; pharmaceutical design services, namely, shaping and designing pills; testing of pharmaceuticals; conducting clinical trials for others relating to pharmaceuticals and chemicals; pharmaceutical analysis, namely, chemical composition analysis, testing, analysis, and evaluation of pharmaceuticals to determine conformity with certification standards; pharmaceutical laboratory research services relating to pharmaceuticals; pharmaceutical product evaluation; inspection of pharmaceuticals; biological research services; quality control and authentication services for others in the field of pharmaceuticals; information, advice and consultancy services in relation to the aforesaid services

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 29, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 29, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 13, 2022 NPUB
PUBLISHED FOR OPPOSITION
Sep 13, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 24, 2022 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 5, 2022 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 2, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 2, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 2, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 2, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 2, 2022 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jul 27, 2022 ZZZX
WITHDRAWN FROM PUB - EXAMINING ATTORNEY REQUEST
Jul 27, 2022 PBER
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 22, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 19, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 19, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 19, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 19, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 30, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 30, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 30, 2022 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 24, 2022 GNFN
FINAL REFUSAL E-MAILED
Jan 24, 2022 GNFR
FINAL REFUSAL WRITTEN
Jan 24, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 28, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 28, 2021 CRFA
ASSIGNED TO LIE
Dec 28, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 23, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 25, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jun 25, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jun 25, 2021 CNRT
ASSIGNED TO EXAMINER
Jun 21, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 10, 2021 NWOS
NEW APPLICATION ENTERED
Dec 26, 2020 NWAP